Valneva's 2025 Outlook Takes a Hit as Key Vaccine Marketing Rights Shift in Brazil
Alarm Bells Ring as Valneva's Groundbreaking Chikungunya Vaccine, IXCHIQ, Faces U.S. Suspension Over Safety Fears